Oral Presentation First Malaria World Congress 2018

Validation of G6PD Biosensors for vivax malaria elimination (#211)

Germana Bancone 1 2 , Gornpan Gornsawun 1 , CIndy S Chu 1 2 , Pimsupah Penpitchaporn 1 , Paw K Moo 1 , Sampa Pal 3 , Pooja Bansil 3 , Gonzalo J Domingo 3 , Francois Nosten 1 2
  1. Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Mae Sot, Thailand
  2. Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  3. Diagnostics Program, PATH, Seattle, USA

Wide spread availability and prescription of primaquine, and in the future tafenoquine, is critical in malaria elimination efforts in areas where Plasmodium vivax is prominent.  However, individuals with G6PD deficiency are at risk to develop acute hemolysis and hemolytic anemia following exposure to 8-aminoquinolines. Safe access to primaquine and tafenoquine will require the ability to discriminate G6PD deficient and intermediate subjects from G6PD normal using simple point-of-care (POC) tests in the field. The aim of the study was to validate two quantitative POC G6PD devices by comparing their performances against the gold standard spectrophotometric assay in a laboratory setting using fresh blood samples with different G6PD phenotypes. The results obtained on the two devices showed unsatisfactory performances in the first one and very good results throughout the full range of G6PD activities in the second one. The next step will be the field validation of the quantitative POC G6PD test to assess stability in tropical environmental conditions and usability among primary health care workers.